Last updated: February 15, 2026
What is NDC 70000-0363?
NDC 70000-0363 is the National Drug Code identifier for Remdesivir (Veklury), an antiviral medication used primarily for treating COVID-19. It was approved by the FDA in October 2020 under Emergency Use Authorization (EUA) and formally approved in October 2020 for hospitalized patients.
Market Size and Demand for Remdesivir
Current Market Context:
- Remdesivir is authorized for hospitalized COVID-19 patients. Its use is driven by the ongoing prevalence of COVID-19 variants and treatment guidelines.
- The initial surge in demand was highly concentrated in the pandemic's early phases. Since then, demand has stabilized but remains significant amid potential new variants.
- Annual treatment courses are estimated at 1.8 million units globally, with the U.S. accounting for approximately 60% of this volume.
Estimated U.S. Market Size:
| Parameter |
Estimate |
| Annual COVID-19 hospitalizations in U.S. |
1.2 million (2022 data) [1] |
| Percentage of hospitalized patients eligible for Remdesivir |
80% |
| Average treatment course per patient |
1 vial |
| Total annual treatment courses in U.S. |
960,000 |
Global Demand:
- The global adoption depends on regulatory approvals outside the U.S., vaccine coverage, and healthcare infrastructure.
- Markets like Europe, Japan, and emerging markets show variable adoption rates.
Pricing Trends and Projections
Historical Pricing:
- The wholesale acquisition cost (WAC) for Remdesivir in the U.S. has ranged from approximately $390 per vial (initial post-EUA) to $520 per vial as of recent data [2].
- The median contractual reimbursement rate varies by payer, hospital procurement programs, and distribution channels.
Current Price Range (U.S.):
| Pricing Metric |
Range |
| Wholesale Acquisition Cost (WAC) |
$390 - $520 per vial |
| Average negotiated price |
$400 - $450 per vial |
| Estimated cost for complete treatment (6 vials) |
$2,340 - $2,700 |
Pricing Factors Influencing Future Trends:
- Market Competition: Limited, as there are no direct alternatives with comparable efficacy.
- Manufacturing Costs: Estimated at approximately $50-$100 per vial; economies of scale may reduce costs.
- Reimbursement and Payer Negotiation: Price concessions could occur based on hospital contracts, government negotiations, or generic competition if patent rights are challenged.
- Supply Chain Dynamics: Manufacturing capacity constraints may cause price volatility.
Projections (Next 1-3 Years)
| Year |
Projected U.S. Market Size |
Predicted WAC per Vial |
Expected Price Trend |
| 2023 |
800,000–900,000 courses |
$400–$450 |
Stable with minor fluctuations |
| 2024 |
700,000–850,000 courses |
$385–$440 |
Slight decline expected; commoditization |
| 2025 |
600,000–800,000 courses |
$370–$420 |
Prices possibly stabilized or lower due to increased competition |
Key assumptions:
- COVID-19 remains endemic with ongoing hospitalizations.
- No major supply disruptions or patent challenges.
- Continued reliance on Remdesivir for hospitalized cases; limited pivot to new therapies.
Regulatory and Competitive Landscape
- Approvals: Currently approved in several jurisdictions beyond the U.S., including Europe (EMA), Japan (PMDA), and Canada.
- Emerging Therapies: Oral antivirals such as Paxlovid (Pfizer) and Molnupiravir (Merck) reduce hospitalizations, possibly curbing REMs demand.
- Generic and Biosimilar Development: No biosimilar versions launched yet; patent protections extend into 2029.
Implications for Stakeholders
- Manufacturers: Stable demand suggests ongoing revenue streams; scale-up could reduce manufacturing costs.
- Payers/Providers: Negotiated prices remain crucial; price ceilings may emerge due to competition from oral agents.
- Investors: Persistent demand supports revenue but warrants monitoring for patent expiry or new entrants.
Key Takeaways
- The U.S. market for NDC 70000-0363 (Remdesivir) centers around approximately 960,000 treatment courses annually.
- Current prices hover between $390 and $520 per vial, with an average around $420–$450.
- Future price projections indicate stability in the short term, with potential slight declines driven by market competition and increased supply.
- Demand is expected to decline gradually over the next three years, but remains significant amid ongoing COVID-19 hospitalizations.
- Market dynamics are influenced by the emergence of new therapies, regulatory decisions, and patent protections.
FAQs
1. What factors could cause Remdesivir prices to rise significantly?
Supply shortages, increased manufacturing costs, or regulatory interventions restricting supply could drive prices upward.
2. How does the availability of oral COVID-19 therapies impact the demand for Remdesivir?
Oral treatments like Paxlovid reduce hospitalization rates, potentially decreasing demand for intravenous therapies, including Remdesivir.
3. When are generic versions of Remdesivir expected to enter the market?
Patent protections are projected to expire around 2029, after which generics could enter the market, reducing prices.
4. Are there geopolitical factors influencing the market for this drug?
Yes. International supply chain disruptions, export restrictions, or political decisions can impact availability and pricing globally.
5. How might future developments alter the current pricing outlook?
Approval of new therapies, changes in hospital treatment protocols, or new regulatory guidelines could impact demand and pricing.
Citations
[1] CDC COVID-19 Hospitalization Data, 2022.
[2] IQVIA, Wholesale Acquisition Cost Data, 2023.
